Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL.

Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x.

2.

Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.

Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, Gorringe KL, James PA, Campbell IG.

J Natl Cancer Inst. 2019 Apr 5. pii: djz045. doi: 10.1093/jnci/djz045. [Epub ahead of print]

PMID:
30949688
3.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL.

J Pathol. 2019 Jul;248(3):326-338. doi: 10.1002/path.5262. Epub 2019 Apr 22.

PMID:
30843206
4.

Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.

McEvoy CR, Xu H, Smith K, Etemadmoghadam D, San Leong H, Choong DY, Byrne DJ, Iravani A, Beck S, Mileshkin L, Tothill RW, Bowtell DD, Bates BM, Nastevski V, Browning J, Bell AH, Khoo C, Desai J, Fellowes AP, Fox SB, Prall OW.

J Clin Invest. 2019 May 1;129(5):1940-1945. doi: 10.1172/JCI123089. Epub 2019 Mar 5.

5.

Molecular comparison of interval and screen-detected breast cancers.

Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG.

J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.

PMID:
30746706
6.

CCL27/CCL28-CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells.

Karnezis T, Farnsworth RH, Harris NC, Williams SP, Caesar C, Byrne DJ, Herle P, Macheda ML, Shayan R, Zhang YF, Yazar S, Takouridis SJ, Gerard C, Fox SB, Achen MG, Stacker SA.

Cancer Res. 2019 Apr 1;79(7):1558-1572. doi: 10.1158/0008-5472.CAN-18-1858. Epub 2019 Feb 1.

PMID:
30709930
7.

Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.

McCart Reed AE, Kalaw E, Nones K, Bettington M, Lim M, Bennett J, Johnstone K, Kutasovic JR, Saunus JM, Kazakoff S, Xu Q, Wood S, Holmes O, Leonard C, Reid LE, Black D, Niland C, Ferguson K, Gresshoff I, Raghavendra A, Harvey K, Cooper C, Liu C, Kalinowski L, Reid AS, Davidson M, Pearson JV, Pathmanathan N, Tse G, Papadimos D, Pathmanathan R, Harris G, Yamaguchi R, Tan PH, Fox SB, O'Toole SA, Simpson PT, Waddell N, Lakhani SR.

J Pathol. 2019 Feb;247(2):214-227. doi: 10.1002/path.5184. Epub 2018 Dec 20.

PMID:
30350370
8.

Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?

Hendry S, Cooper WA, Fox SB.

J Thorac Oncol. 2018 Sep;13(9):e185-e186. doi: 10.1016/j.jtho.2018.04.029. No abstract available.

9.

Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0176-6.

PMID:
30135555
10.

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Jul;24(7):986-993. doi: 10.1038/s41591-018-0078-7. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29942092
11.

SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response.

McEvoy CR, Koe L, Choong DY, Leong HS, Xu H, Karikios D, Plew JD, Prall OW, Fellowes AP, Fox SB.

NPJ Precis Oncol. 2018 Mar 20;2:9. doi: 10.1038/s41698-018-0053-2. eCollection 2018.

12.

Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting.

Lee B, Tran B, Hsu AL, Taylor GR, Fox SB, Fellowes A, Marquis R, Mooi J, Desai J, Doig K, Ekert P, Gaff C, Herath D, Hamilton A, James P, Roberts A, Snyder R, Waring P, McArthur G.

Intern Med J. 2018 Jul;48(7):786-794. doi: 10.1111/imj.13806.

PMID:
29607586
13.

Canary: an atomic pipeline for clinical amplicon assays.

Doig KD, Ellul J, Fellowes A, Thompson ER, Ryland G, Blombery P, Papenfuss AT, Fox SB.

BMC Bioinformatics. 2017 Dec 15;18(1):555. doi: 10.1186/s12859-017-1950-z.

14.

Invasion in breast lesions: the role of the epithelial-stroma barrier.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, Wentao Y, Geyer FC, Reis-Filho JS, Pinder SE, Lakhani SR, Ellis IO.

Histopathology. 2018 Jun;72(7):1075-1083. doi: 10.1111/his.13446. Epub 2018 Feb 13. Review.

PMID:
29197112
15.

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer.

Hendry S, Byrne DJ, Wright GM, Young RJ, Sturrock S, Cooper WA, Fox SB.

J Thorac Oncol. 2018 Mar;13(3):367-376. doi: 10.1016/j.jtho.2017.11.112. Epub 2017 Nov 23.

16.

LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.

Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA, Clyne C, Gorringe KL, Dobrovic A, Fox SB.

Oncotarget. 2017 Jul 28;8(48):83626-83636. doi: 10.18632/oncotarget.18886. eCollection 2017 Oct 13.

17.

Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Gorringe KL, Fox SB.

Front Oncol. 2017 Oct 23;7:248. doi: 10.3389/fonc.2017.00248. eCollection 2017. Review.

18.

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.

Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G.

Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3.

19.

Precision oncology using a clinician-directed, tailored approach to molecular profiling.

Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox SB, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal MA, Desai J.

Asia Pac J Clin Oncol. 2018 Feb;14(1):84-90. doi: 10.1111/ajco.12787. Epub 2017 Oct 30.

PMID:
29083093
20.

Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling.

Williams SP, Odell AF, Karnezis T, Farnsworth RH, Gould CM, Li J, Paquet-Fifield S, Harris NC, Walter A, Gregory JL, Lamont SF, Liu R, Takano EA, Nowell CJ, Bower NI, Resnick D, Smyth GK, Coultas L, Hogan BM, Fox SB, Mueller SN, Simpson KJ, Achen MG, Stacker SA.

Sci Signal. 2017 Oct 3;10(499). pii: eaal2987. doi: 10.1126/scisignal.aal2987.

PMID:
28974649
21.

BRCA2 carriers with male breast cancer show elevated tumour methylation.

Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB.

BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.

22.

HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.

Kumarasinghe MP, Morey A, Bilous M, Farshid G, Francis G, Lampe G, McCue G, Von Neumann-Cosel V, Fox SB.

Pathology. 2017 Oct;49(6):575-581. doi: 10.1016/j.pathol.2017.05.009. Epub 2017 Aug 18.

PMID:
28823752
23.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

24.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

25.

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

John T, Bowden JJ, Clarke S, Fox SB, Garrett K, Horwood K, Karapetis CS.

Asia Pac J Clin Oncol. 2017 Aug;13(4):296-303. doi: 10.1111/ajco.12699. Epub 2017 Jul 12. Review.

PMID:
28699260
26.

The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.

Paquet-Fifield S, Roufail S, Zhang YF, Sofian T, Byrne DJ, Coughlin PB, Fox SB, Stacker SA, Achen MG.

Growth Factors. 2017 Jun;35(2-3):61-75. doi: 10.1080/08977194.2017.1349765. Epub 2017 Jul 11.

PMID:
28697634
27.

Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.

Najdawi F, Crook A, Maidens J, McEvoy C, Fellowes A, Pickett J, Ho M, Nevell D, McIlroy K, Sheen A, Sioson L, Ahadi M, Turchini J, Clarkson A, Hogg R, Valmadre S, Gard G, Dooley SJ, Scott RJ, Fox SB, Field M, Gill AJ.

Pathology. 2017 Aug;49(5):457-464. doi: 10.1016/j.pathol.2017.05.004. Epub 2017 Jun 30.

PMID:
28669579
28.

Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.

Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL, Fox SB.

Clin Cancer Res. 2017 Sep 1;23(17):5210-5217. doi: 10.1158/1078-0432.CCR-17-0743. Epub 2017 Jun 13.

29.

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.

Weeden CE, Holik AZ, Young RJ, Ma SB, Garnier JM, Fox SB, Antippa P, Irving LB, Steinfort DP, Wright GM, Russell PA, Ritchie ME, Burns CJ, Solomon B, Asselin-Labat ML.

Mol Cancer Ther. 2017 Aug;16(8):1610-1622. doi: 10.1158/1535-7163.MCT-17-0174. Epub 2017 Jun 13.

30.

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.

31.

Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma.

Tan L, Alexander M, Officer A, MacManus M, Mileshkin L, Jennens R, Herath D, de Boer R, Fox SB, Ball D, Solomon B.

Intern Med J. 2018 Jan;48(1):37-44. doi: 10.1111/imj.13491.

PMID:
28544061
32.

E6AP promotes prostate cancer by reducing p27 expression.

Raghu D, Paul PJ, Gulati T, Deb S, Khoo C, Russo A, Gallo E, Blandino G, Chan AL, Takano E, Sandhu SK, Fox SB, Williams S, Haupt S, Gamell C, Haupt Y.

Oncotarget. 2017 Jun 27;8(26):42939-42948. doi: 10.18632/oncotarget.17224.

33.

PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories.

Doig KD, Fellowes A, Bell AH, Seleznev A, Ma D, Ellul J, Li J, Doyle MA, Thompson ER, Kumar A, Lara L, Vedururu R, Reid G, Conway T, Papenfuss AT, Fox SB.

Genome Med. 2017 Apr 24;9(1):38. doi: 10.1186/s13073-017-0427-z.

34.

Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.

Cooper WA, Russell PA, Cherian M, Duhig EE, Godbolt D, Jessup PJ, Khoo C, Leslie C, Mahar A, Moffat DF, Sivasubramaniam V, Faure C, Reznichenko A, Grattan A, Fox SB.

Clin Cancer Res. 2017 Aug 15;23(16):4569-4577. doi: 10.1158/1078-0432.CCR-17-0151. Epub 2017 Apr 18.

35.

Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.

Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL, Fox SB.

Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24.

36.

GATA3 expression in triple-negative breast cancers.

Byrne DJ, Deb S, Takano EA, Fox SB.

Histopathology. 2017 Jul;71(1):63-71. doi: 10.1111/his.13187. Epub 2017 Apr 19.

PMID:
28211079
37.

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.

Rogers TM, Arnau GM, Ryland GL, Huang S, Lira ME, Emmanuel Y, Perez OD, Irwin D, Fellowes AP, Wong SQ, Fox SB.

Sci Rep. 2017 Feb 9;7:42259. doi: 10.1038/srep42259.

38.

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, Ping-Chang S, Tannapfel A, Reinacher-Schick A, Uhl W, Teschendorf C, Wolters H, Stern J, Viebahn R, Friess H, Janssen KP, Nitsche U, Slotta-Huspenina J, Pohl M, Vangala D, Baraniskin A, Dockhorn-Dworniczak B, Hegewisch-Becker S, Ronga P, Edelstein DL, Jones FS, Hahn S, Fox SB.

Mol Oncol. 2017 Feb;11(2):208-219. doi: 10.1002/1878-0261.12023. Epub 2017 Jan 20.

39.

MDM4 is a rational target for treating breast cancers with mutant p53.

Miranda PJ, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, Haupt Y.

J Pathol. 2017 Apr;241(5):661-670. doi: 10.1002/path.4877. Epub 2017 Mar 1.

PMID:
28097652
40.

Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.

Gamell C, Gulati T, Levav-Cohen Y, Young RJ, Do H, Pilling P, Takano E, Watkins N, Fox SB, Russell P, Ginsberg D, Monahan BJ, Wright G, Dobrovic A, Haupt S, Solomon B, Haupt Y.

Sci Signal. 2017 Jan 10;10(461). pii: eaaf8223. doi: 10.1126/scisignal.aaf8223.

PMID:
28074012
41.

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.

Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB.

Front Immunol. 2016 Dec 20;7:621. doi: 10.3389/fimmu.2016.00621. eCollection 2016. Review.

42.

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.

Luen SJ, Savas P, Fox SB, Salgado R, Loi S.

Pathology. 2017 Feb;49(2):141-155. doi: 10.1016/j.pathol.2016.10.010. Epub 2016 Dec 31.

PMID:
28049579
43.

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue.

Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, Byrne D, Fox SB, Mir Arnau G, Tothill RW, Campbell IG, Gorringe KL.

Genome Med. 2016 Nov 15;8(1):121.

44.

Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis.

Huo CW, Waltham M, Khoo C, Fox SB, Hill P, Chen S, Chew GL, Price JT, Nguyen CH, Williams ED, Henderson M, Thompson EW, Britt KL.

Breast Cancer Res. 2016 Oct 25;18(1):106.

45.

Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program.

Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, von Neumann-Cosel V, Bilous M.

Pathology. 2016 Oct;48(6):535-42. doi: 10.1016/j.pathol.2016.05.007. Epub 2016 Aug 25.

PMID:
27567228
46.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.

Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, Fox SB, Roviello F, Polom K, Bottini A, Generali D.

Breast. 2016 Oct;29:55-61. doi: 10.1016/j.breast.2016.07.003. Epub 2016 Jul 16.

PMID:
27428471
47.

Apatinib for the treatment of gastric cancer.

Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):887-92. doi: 10.1080/17474124.2016.1209407. Epub 2016 Jul 15. Review.

PMID:
27376400
48.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R.

Mod Pathol. 2016 Oct;29(10):1155-64. doi: 10.1038/modpathol.2016.109. Epub 2016 Jul 1.

49.

Is it time for everolimus-based combination in castration-resistant prostate cancer?

Roviello G, Ravelli A, Barni S, Petrelli F, Bottini A, Fox SB, Generali D.

Future Oncol. 2016 Aug;12(16):1849-52. doi: 10.2217/fon-2016-0136. Epub 2016 Jun 2. No abstract available.

50.

Assessing Tumor Angiogenesis in Histological Samples.

Pang JM, Jene N, Fox SB.

Methods Mol Biol. 2016;1430:3-33. doi: 10.1007/978-1-4939-3628-1_1.

PMID:
27172943

Supplemental Content

Support Center